CareDx Raises 2026 Guidance to $490–$500M, Unveils New Transplant Assay Data
CDNA has more than doubled off its 52-week low of $11.259 on elevated volume (3.0× avg).
Summary
CareDx raised its full-year 2026 revenue guidance to $490–$500 million, up from prior expectations, following a 52% surge in Q2 revenue to $132 million. The quarter included a $113 million gain from the lab products sale, but testing services also grew to $99.9 million. New data releases for AlloSure, HistoMap, and NavDx strengthen the clinical evidence for its transplant rejection tests, which could support further adoption. The company also granted 15,822 restricted stock units to a new executive advisor, a minor but positive governance signal. This follows the Medicare LCD confirmation in July that solidified reimbursement for molecular transplant testing, a key catalyst for the testing business.
At the time of this announcement, CDNA was trading at $44.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $11.26 to $45.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.